Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance - CANF News | RalliesCan-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance
C
CANF• Phase III liver cancer and psoriasis programs advance
- Can-Fite highlighted late-stage progress for two oral drug candidates, with pivotal Phase III programs underway for liver cancer and plaque psoriasis.
- No clinical results were reported; the liver cancer study is positioned to support future US and European filings if endpoints are met.
- Namodenoson is being tested in advanced hepatocellular carcinoma patients with Child-Pugh B7 cirrhosis under FDA and EMA regulatory guidance.
- Regulatory positioning includes FDA Fast Track for Namodenoson, with Orphan Drug designations in the US and Europe.
- Piclidenoson remains in Phase III development in moderate-to-severe plaque psoriasis, reinforcing the company’s late-stage pipeline focus.
